Display Settings:

Format
Items per page

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 1 to 20 of 114

1.

Topoisomerase II Inhibitors

A substance that interacts with topoisomerase II and inhibits its activity. A topoisomerase II inhibitor can either stabilize the DNA-protein complex or inhibit the catalytic activity of the enzyme. Despite their differences in action, these agents all block cells in G2/M. [from NCI]

MedGen UID:
275487
Concept ID:
C1519554
Pharmacologic Substance
2.

leukemia

A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) [from MeSH]

MedGen UID:
9725
Concept ID:
C0023418
Neoplastic Process
3.

Leukemia

A cancer of the blood and bone marrow characterized by an abnormal proliferation of leukocytes. [from HPO]

MedGen UID:
505002
Concept ID:
CN001727
Finding
4.

Neuroblastoma

ALK-related neuroblastoma susceptibility occurs in individuals who are heterozygous for a germline ALK mutation and is characterized by an increased risk of developing neuroblastoma, ganglioneuroblastoma, or ganglioneuroma. The risk for tumor development is highest in infancy and decreases by late childhood. Individuals with familial neuroblastoma tend to develop tumors at a younger age (average 9 months) than those without familial predisposition (age 2-3 years). [from GeneReviews]

MedGen UID:
18012
Concept ID:
C0027819
Neoplastic Process
5.

Diagnosis

The process of identifying a disease, such as cancer, from its signs and symptoms. [from NCI]

MedGen UID:
8354
Concept ID:
C0011900
Finding
6.

Growth arrest

MedGen UID:
569472
Concept ID:
C0333951
Pathologic Function
7.

Acute myeloid leukemia

A form of leukemia characterized by overproduction of an early myeloid cell. [from HPO]

MedGen UID:
505691
Concept ID:
CN004254
Finding
8.

Neuroblastoma

Neuroblastoma is a solid tumor that originate in neural crest cells of the sympathetic nervous system. Most neuroblastomas originate in the abdomen, and most abdominal neuroblastomas originate in the adrenal gland. Neuroblastomas can also originate in the thorax, usually in the posterior mediastinum. [from HPO]

MedGen UID:
505432
Concept ID:
CN002717
Finding
9.

Acute

Symptoms or signs that begin and worsen quickly; not chronic. [from NCI]

MedGen UID:
61381
Concept ID:
C0205178
10.

Complication

In medicine, a medical problem that occurs during a disease, or after a procedure or treatment. The complication may be caused by the disease, procedure, or treatment or may be unrelated to them. [from NCI]

MedGen UID:
40429
Concept ID:
C0009566
Pathologic Function
11.

AML - Acute myeloid leukemia

Familial acute myeloid leukemia (AML) with mutated CEBPA is defined as AML in which a germline CEBPA mutation is present in a family in which multiple individuals have AML. In contrast, sporadic AML with mutated CEBPA is defined as AML in which a CEBPA mutation is identified in somatic (i.e., leukemic) cells but not in germline (i.e., non-leukemic) cells. Too few persons with familial AML with mutated CEBPA have been reported to be certain about the natural history of the disease. The age of onset of familial AML with mutated CEBPA appears to be earlier than sporadic AML; disease onset has been reported in persons as young as age four years and older than age 50 years. The prognosis of individuals with familial AML with mutated CEBPA appears to be favorable (~50%-65% overall survival) compared to the ~25%-40% overall survival of those who have normal karyotype AML but no germline CEPBA mutation. Individuals with familial AML with mutated CEBPA who have been cured of their initial disease may be at greater risk of developing additional malignant clones than persons with sporadic disease. [from GeneReviews]

MedGen UID:
9730
Concept ID:
C0023467
Neoplastic Process
12.

Myeloid leukemia

Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. [from MeSH]

MedGen UID:
7320
Concept ID:
C0023470
Neoplastic Process
13.

Cytophosphan

MedGen UID:
501178
Concept ID:
C3495431
Pharmacologic Substance
14.

Peripheral neuroepithelioma

MedGen UID:
483352
Concept ID:
C3489398
Neoplastic Process
15.

Adriblastin

MedGen UID:
423645
Concept ID:
C2936928
Pharmacologic Substance
16.

Eto-GRY

MedGen UID:
327829
Concept ID:
C1564686
Pharmacologic Substance
17.

Celltop

MedGen UID:
327828
Concept ID:
C1564684
Pharmacologic Substance
18.

Farmiblastina

MedGen UID:
307476
Concept ID:
C1512059
Pharmacologic Substance
19.

Onkodox

MedGen UID:
297409
Concept ID:
C1564916
Pharmacologic Substance
20.

Eposin

MedGen UID:
297354
Concept ID:
C1564685
Pharmacologic Substance

Display Settings:

Format
Items per page

Send to:

Choose Destination

Supplemental Content

Find related data

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...